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Abstract
Objectives Children with autism spectrum disorder (ASD) have been found to have a high prevalence of folate receptor auto-
antibodies (FRAA), which may impair the normal transport of folate from blood into the cerebrospinal fluid (CSF). Leucovorin
calcium (LC) is believed to bypass the folate transport system and restore function. We sought to examine changes in behavior
and urinary metabolites in children and young adults with ASD being treated with LC.
Methods Students attending a K-12 school for ASD were recruited for an open-label, 12-week study of high-dose LC (2 mg/kg/
day, max dose 50 mg/day). The primary outcome measures were the mean changes in the Aberrant Behavior Checklist (ABC)
and the Social Responsiveness Scale (SRS). We also examined changes in Pediatric Quality of Life (PedsQL) and urinary
metabolites. Changes were assessed with paired sample t-tests.
Results Twelve students aged 13 to 19 (2 girls, 10 boys) completed the study. The parent-reported SRS showed a non-significant
decrease (improvement) of 7.8 points (95% CI − 1.6 to 17.3, p = 0.095), and the ABC showed a non-significant decrease of 2.4
points (95% CI − 6.4 to 11.3, p = 0.56). The teacher-reported ABC and the parent-reported PedsQL showed very little change.
Urinary metabolites with the greatest changes were involved in folate, phosphatidylcholine, and tocopherol metabolism.
Conclusions In an open-label study of school-aged children with ASD, LC treatment did not lead to significant improvements.
The parent-reported SRS showed a non-significant improvement of 7.8 points, which is clinically important and worthy of future
study with larger samples. The potential benefits of LCmay be limited to children with a specific physiological abnormality (e.g.,
FRAA status) and may require a targeted treatment approach. Urinary metabolites may be a useful tool to identify children who
are likely to respond to treatment.
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Prior studies have linked abnormalities in the metabolism of
folate, an essential B vitamin, to autism spectrum disorder
(ASD) (Vahabzadeh and McDougle 2013). Children with ASD
have been found to have impaired transport of folate across the
blood-brain barrier due to auto-antibodies that either block or
bind to the folate receptor alpha (FR alpha). The antibodies are
known as folate receptor auto-antibodies (FRAA). This creates
the condition known as “cerebral folate deficiency,” which de-
scribes an individual with normal serum folate concentrations but
low concentrations of folate in the cerebrospinal fluid (CSF) due
to impaired ability to transport folate across the blood-brain bar-
rier (Frye et al. 2018). Folate is believed to have many essential
functions in the central nervous system. Folate is a component of
tetrahydrofolate, which is a cofactor involved in DNA methyla-
tion and neurotransmitter synthesis and degradation. Low folate
levels in the CSF have been implicated in neural tube defects,
neurodegenerative diseases, neuropsychiatric diseases, and can-
cer (Stover et al. 2017).
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Children with ASD have been found to have a high prev-
alence of FRAA. In a study of 93 childrenwith ASD, 60% had
blocking FRAA, and 44% had binding FRAA (Frye et al.
2013). Blocking antibodies interfere with binding of folate
to the FR alpha, and binding antibodies bind to the FR alpha
and cause an antibody-mediated immune reaction. Both anti-
bodies interfere with the normal transport of folate into the
CSF. The rates of FRAA in ASD are higher than the 4–15%
prevalence reported in healthy adults and the 3% prevalence
reported in developmentally delayed non-autistic children
(Frye et al. 2018). Up to 23% of children with ASD who
underwent lumbar puncture were reported to have abnormally
low CSF folate concentrations (Shoffner et al. 2016).
Together, this evidence suggests that low CSF folate levels
may contribute to the abnormal physiology and clinical symp-
toms of ASD.
Leucovorin calcium (LC—the drug name for folinic acid),
a reduced form of folate, is able to bypass the normal blood-
brain barrier transport mechanism and increase CSF folate
levels through a secondary transport mechanism. Case reports
have found that high-dose LC supplementation markedly im-
proves CSF folate levels in children with ASD and low CSF
folate (Frye et al. 2018). In a recent randomized controlled
trial of LC supplementation vs. placebo in 48 children with
ASD and language delay, children randomized to LC had
statistically significant improvements in language and aber-
rant behavior (Frye et al. 2018). Furthermore, improvements
were greater in the subgroup of children who were positive for
FRAA, suggesting that children with more severe cerebral
folate deficiency were more likely to benefit.
Since folate is involved in DNA synthesis, cellular meth-
ylation, and redox homeostasis, and an adequate cerebral sup-
ply of folate may allow for improved functioning of these
pathways and clinical improvements. In order to further ex-
amine the efficacy of LC in children with ASD, we conducted
an open-label study to determine if treatment would lead to
clinical improvements and whether there would be associated
changes in urinary metabolites, which might suggest a mech-
anism of action and help identify children most likely to
benefit.
Methods
Participants
Parents and/or caregivers of children and young adults be-
tween the ages of 5 and 22 who were enrolled at the Oak
Hill School (OHS) in San Anselmo, CA (a school for children
with autism or related neurodevelopmental disorders), were
recruited by e-mail to participate in the study. Participants
were required to be enrolled at OHS, between the ages 5 and
22 and with a diagnosis of ASD (as established by expert
clinician review of DSM-V criteria and meeting a threshold
score on the Social Communication Questionnaire). Children
were excluded if they had a co-existing condition that, in the
opinion of the investigator, would compromise the safety of
the patient or the quality of the data or if they had a known
allergy to any component of the LC product or if they were
currently taking LC or had used this supplement in the last
6 months.
Eighteen children were enrolled in the study at initiation;
six children dropped out of the study, and twelve children
completed the study. Reasons for drop-outs were as follows:
(1) increased depression, (1) more easily upset, (1) emotion-
ally sensitive, (1) hyperactivity, (1) diarrhea, and (1) migraine.
None of the adverse effects that led to drop-outs were judged
to be likely due to treatment. Table 1 shows the characteristics
of the children who completed the study (n = 12). Most stu-
dents were male (83.3%) and between the ages of 13 and 17
(75.0%).
Procedure
Minor students and adult students who were under legal con-
servatorship went through an informed consent process and
provided verbal assent, while their parents or guardians pro-
vided informed consent. Young adults (age 18 and over) who
were not conserved by their parents provided their own con-
sent. Students were excluded if they were not interested/
willing to participate in the program or the student or
parents/caregivers were not willing to fill out study surveys.
Study participants were provided with LC capsules and ad-
vised to take them twice a day with meals for 12 weeks. The
capsules are dye-free, milk product-free, vegetarian, and avail-
able in 3 strengths (5, 10, and 25 mg) and were provided with
instructions for weight-based dosing (2 mg/kg with maximum
dose of 50 mg/day divided in two doses). The capsules were
produced by Lee Silsby Pharmacy (Cleveland Heights, OH).
A certificate of analysis was obtained by an independent ana-
lytical service, and an investigational new drug packet was
approved by the FDA. Participants were advised to swallow
the capsules with water or juice, or, if this was not possible,
they were advised to pierce the capsule and mix the contents
into soft food including yogurt, oatmeal, and drinks and then
consume the mixed material.
Measures
All outcome measures were assessed monthly, and the prima-
ry outcomes of interest were change in mean scores from
baseline to close-out (12 weeks).
The Aberrant Behavior Checklist (ABC), community ver-
sion, is a 58-item rating scale that measures aberrant behavior
in children and young adults with neurodevelopmental disor-
ders and it is a commonly used outcome measure in clinical
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trials of interventions for ASD (Bent et al. 2014; Hardan et al.
2012). Studies examining the factor structure of the ABC and
comparisons to other scales have demonstrated convergent
and divergent validity of the scale (Kaat et al. 2014).
The Social Responsiveness Scale (SRS) is a 65-item rating
scale that assesses the severity of social impairment in indi-
viduals with ASD. The scale has been shown to have both
good sensitivity and specificity be able to distinguish ASD
from other childhood psychiatric conditions (Duku et al.
2013). The SRS is commonly used to assess social reciprocity
in studies of interventions for ASD (Bent et al. 2014; Hardan
et al. 2012) and has high inter-rater reliability between parents
(Pearl et al. 2013).
The Pediatric Quality of Life (PedsQL) scale measures
overall quality of life and has been used in hundreds of studies
of children and young adults with medical and psychiatric
disease. PedsQL has demonstrated high reliability and con-
struct validity in healthy, acute, and chronic disease pediatric
populations. It is responsive to change and is therefore appro-
priate for use in clinical trials (Fitzpatrick et al. 2020).
Urinary metabolites were measured for all participants at
screening and close-out (0 and 12 weeks). Parents were
instructed to assist the study participant with a home urine
collection in a sterile container provided by the study team
(fasting, 8 a.m. target collection time) and then immediately
place the urine sample in their home freezer. A member of the
study team picked up the urine sample on the samemorning; it
was collected and transported in a cooler with ice to the lab-
oratory, where it was placed in a – 80 °C freezer, generally
within 1–2 h of collection. Metabolomic assessment was con-
ducted by Metabolon (Research Triangle, NC), and urinary
metabolites were normed per gram of creatinine in the urine
sample. Metabolon is one of the largest and most established
laboratories conducting state-of-the art metabolomics assess-
ments of urine, plasma, and other clinical samples (www.
metabolon.com).
Table 1 Baseline characteristics
Characteristics Number Percentage
Gender
Male 10 83.3%
Female 2 16.7%
Age group (years)
13–17 9 75.0%
≥ 18 3 25.0%
Mean age (SD) 16.3 (1.5)
Race
Caucasian 9 75.0%
More than one race 3 25.0%
Medical comorbidities present
Yes
Expressive language disorder 2 16.7%
Mixed receptive-expressive language disorder 1 8.3%
Speech and Language Impairment 1 8.3%
Other 2 16.7%
No or not reported 8 66.7%
Current medication use
Yes
Anticonvulsant medications 1 8.3%
Anti-depressant medications 5 41.7%
Anti-psychotic medications 3 25.0%
GI medications 1 8.3%
Sedative medications 2 16.7%
Stimulants 2 16.7%
Other medications 2 16.7%
No or not reported 3 25.0%
Supplement use
Yes 4 33.3%
No or not reported 8 66.7%
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Safety was assessed monthly by asking parents and care-
givers whether their child had experienced any adverse med-
ical events or potential side effects while taking LC treatment.
Parents/caregivers were also instructed to contact the study
team immediately if the participant had any new medical
problem that might represent an adverse event. Reported ad-
verse events were summarized in a tabular format.
Data Analyses
We examined the trajectory of change in the mean score of
ABC, SRS, and PedsQL at baseline and week 12 using paired
sample t-test. Differences between paired subjects for SRS
teacher total scores were not normally distributed using
Shapiro-Wilk test, so we used a paired two-sample
Wilcoxon test for SRS teacher total scores. We also measured
urinary metabolites at baseline and week 12 to examine their
fold of change. All the analysis were conducted using R
Studio Version 1.1.456. Because this study is exploratory in
nature, no adjustments were made for multiple comparisons,
as recommended by Rothman (Rothman 1990).
We conducted a power analysis to determine the ability of
this small study to detect a change in social responsiveness. We
defined a large change in social responsiveness (SRS) as an
effect size of 0.8 (which corresponds to the minimal clinically
important difference of 10) and used the standard deviation of
the change of the SRS of 12 (from our prior studies). With our
sample size of 12 and an alpha of 0.05, the power of this study
to detect this specified level of changewas 50%,which is below
the standard of 80% often used for larger clinical trials, but
expected for a small, early intervention study.
Results
Table 2 shows the change in mean difference in all outcome
measures before (baseline) and after the children took LC
(week 12). None of the observed changes were statistically
significant. The parent-reported mean of the differences in
SRS showed the biggest change of a non-significant decrease
(improvement) of 7.8 points (95%CI − 1.6 to 17.3, p = 0.095).
The parent-reported ABC showed a non-significant decrease
(improvement) of 2.4 points (95% CI − 6.4 to 11.3, p = 0.56),
and the teacher-reported ABC showed a non-significant in-
crease (worsening) of 1.2 points (95% CI -5.2 to 7.6, p =
0.68). The parent-reported PedsQL showed a non-significant
decrease (worsening) of 0.8 points (95% CI − 3.5 to 5.2, p =
0.69).
As shown in Table 3, the urinary metabolites with the larg-
est change over the course of the study (and their associated
fold change) were as follows: 5-methyltetrahydrofolate (24.8),
1-stearoyl-2-arachidonoyl-GPC (10.1), 1-stearoyl-2-oleoyl-
GPC (9.3), alpha-tocopherol (9.2), and 1-stearoyl-2-
linoleoyl-GPC (7.8).
Adverse events were uncommon in participants who com-
pleted the study. Five adverse events were reported over the
12-week period, and none were judged to be serious or likely
to be caused by the LC (1 each of upset stomach, dry mouth,
cold, increased aggression, and blood in stool).
Discussion
In this open-label study in an unselected, small sample of
school-aged children with ASD who were treated with a 12-
week course of LC, we did not find statistically significant
improvements in behavior, social responsiveness, or quality
of life. Interestingly, there was a non-significant improvement
in social responsiveness as assessed by parents (7.8 points,
effect size = 0.52) which is a medium effect size. While a
minimal clinically important difference (MCID) for the SRS
in children with autism has not been determined in children
with ASD, some authors have suggested using a change in the
SRS of > 10 to indicate a MCID and to address the concern
that smaller changes may be within the range of a placebo
effect (Hardan et al. 2019). The non-significant change of
Table 2 Changes in mean total
scores in each of the outcome
measures over time
Outcome measure Caregiver Teacher
Mean
change
95% CI p
value
Mean
change
95% CI p
value
Aberrant Behavior
Checklist
− 2.4 − 11.3 to
6.4
0.56 1.2 − 5.2 to 7.6 0.68
Social Responsiveness
Scale
− 7.8 − 17.3 to
1.6
0.095 − 1.7 − 10.56 to
7.16
0.95*
Pediatric Quality of Life − 0.8 − 5.2 to 3.5 0.69
p < 0.05 indicates statistical significance. *The p value for SRS teacher total scores was analyzed by using paired
Wilcoxon test since the difference between paired subjects for SRS teacher total scores were not normally
distributed using Shapiro-Wilk test. The Pediatric Quality of Life was completed only by the caregivers and
not the teachers
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7.8 points observed in this study is below this proposedMCID
threshold but still a signal of a large enough change to warrant
further investigation in larger, placebo-controlled studies. As
previously mentioned, one prior randomized controlled trial of
LC treatment for 12 weeks in children with ASD found statis-
tically significant improvements in behavior and language
compared with children treated with placebo (Frye et al.
2018). In that study, children who were positive for the
FRAA-autoantibody showed greater improvements than those
without the antibody, suggesting that LC may be most bene-
ficial in this subset of children. Our study did not include
measures of the FRAA antibody, but selection of subjects
who are positive for this antibody may increase the likelihood
of observing beneficial effects.
This study examined changes in urinary metabolites during
treatment with LC.We found that the urinary metabolites with
the largest increases during treatment were related to folate
metabolism, phosphatidylcholine, and tocopherol. Although
our study had insufficient power to assess the predictive value
of these metabolites, larger samples may be able to target these
biomarkers to determine if patients with certain urinary pro-
files are more likely to benefit from treatment.
Limitations and Future Research Direction
Our study was limited by the small sample size in a hetero-
geneous school population and lack of a control group. The
finding of a non-significant improvement in social respon-
siveness with a medium effect size is intriguing and sug-
gests that a larger study with greater power might find an
important therapeutic benefit to LC. It is also possible that a
beneficial effect would be larger if the study were limited to
participants who are FRAA positive. Although a prior study
of LC treatment in children with autism found benefits
mostly in speech and communication (Frye et al. 2018),
we sought to determine if changes would be found in more
global measures of social interaction (SRS), behavior
(ABC), and overall quality of life (PedsQL) in a population
of school children without requiring subjects to have a spe-
cific language impairment. Of note, both the SRS and ABC
include questions related to communication and speech. Six
subjects dropped out of the study for various reasons, and
there were a small number of minor adverse events. The
frequency of most of the reasons cited for dropping out is
high in this population, so it is not clear if LC contributed to
these negative symptoms. Our clinical judgment is that the
treatment was generally well tolerated but we advise clini-
cal monitoring in any child who elects to try LC. Future
studies might also consider a more gradual increase in does
to avoid any possible dose-related side effects.
In summary, there is an interesting physiological rationale
to suggest that LC treatment may be beneficial in children
with ASD, particularly those who are FRAA positive.
Although we did not find a statistically significant benefit,
our study was limited by a small sample size, and the magni-
tude of the observed change is still consistent with a clinically
important beneficial effect. We recommend that a large, ran-
domized, placebo-controlled trial be conducted, ideally in par-
ticipants who are screened for FRAA antibody status. Urinary
metabolites in a larger sample hold promise for both observing
a mechanism of action and predicting a subset of patients who
may be more likely to benefit from treatment.
Table 3 Selected urinary metabolites with statistically significant changes from 0 to 12 weeks
Category Sub-pathway Biochemical name Fold of change p Value
Folate metabolism Folate metabolism 5-Methyltetrahydrofolate 24.8 0.03
Lipid Phosphatidylcholine 1-Stearoyl-2-arachidonoyl-glycerophosphocholine 10.1 > 0.01
Lipid Phosphatidylcholine 1-Stearoyl-2-oleoyl-glycerophosphocholine 9.3 0.04
Lipid Tocopherol metabolism Alpha-tocopherol 9.2 > 0.01
Lipid Phosphatidylcholine 1-Stearoyl-2-linoleoyl-glycerophosphocholine 7.8 > 0.01
Neurotransmitter Acetylated peptides 3-Hydroxyphenylacetoyl-glutamine 0.5 0.02
Neurotransmitter Glutamate Carboxymethyl-GABA 1.6 > 0.01
Neurotransmitter Glutamate Gamma-carboxyglutamate 1.6 0.02
Neurotransmitter Tyrosine Dopamine 1.4 > 0.01
Redox indicator Methionine Methionine sulfoxide 1.6 0.02
Redox indicator Methionine Cystathionine 1.5 0.048
Redox indicator Methionine Cystine s-sulfate 1.4 0.01
Redox indicator Methionine N-acetylcysteine 0.6 0.048
Redox indicator Methionine Alpha-ketobutyrate 0.4 0.01
Fold changes > 1.0 indicate an increase, and < 1.0 indicate a decrease in the urinary metabolite from 0 to 12 weeks. GABA indicates gamma
aminobutyric acid
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